Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TGEN - Targeted Genetics Corporation -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (469)	5/30/2006 10:17:41 AM
From: 9wald9	Respond to of 557

Let us assume that the institutional investors whom on 3/10/2006 purchased 1.28 million (post 1 for 10 reverse split) TGEN shares for $3.90 a share were not philanthropists. Those investors received a 25% discount from the then market share price Today a share of TGEN is selling for about $2.50. That is a more than a 35% discount from the institutional investors buying price. I like to buy shares under these circumstances if there is no apparent reason for the discount. The first week of June Targeted Genetics is to make a presentations on its product development programs. If we hear good things about the Preliminary Phase I/II data from an ongoing trial of tgAAC94 in patients with inflammatory arthritis, there could be some excitement about the stock. We know the drug works and has been approved by the FDA. Can the delivery system do its job? Now seems the time to make a bet on TGEN.